What if you develop side effects after immunisation? The Government has a plan
It is completely normal for people to develop side effects after immunisation. In medical jargon, these side effects are called adverse events. These can be 'minor', 'severe', or 'serious', with only the last category requiring hospitalisation. In fact, vaccination drives that are underway the UK and the US have also reported adverse events, especially in people with allergies, says the writer of this article. None were 'serious'.
The top three vaccines that are currently awaiting the government's approval in India are Pfizer and BioNTech, Oxford-AstraZeneca and Bharat Biotech's Covaxin. So far, the adverse events have been 'minor' or 'severe', and the proportion of such cases has been small.
Are Covid-19 vaccines safe and efficient? A virologist answers burning questions
Covishield being developed by Oxford-AstraZeneca and manufactured by India's Serum Institute, Covaxin being developed by Bharat Biotech, and the vaccine candidate developed by Pfizer and BioNTech are in line to receive emergency approval for Covid-19 vaccination in India. But, several large-scale surveys have indicated significant vaccine hesitancy in the general public, including among health professionals.
Dr Shahid Jameel, a virologist and the director of the Trivedi School of Biosciences at Ashoka University, answers burning questions around vaccine hesitancy, including around safety, efficacy, adverse events, and the rapid speed with which vaccine development has taken place.
Watch here What supply-chain ideas of Amazon, Walmart can help cut Covid-19 vaccine waste
Complicated storage requirements and variability in demand are two key challenges of vaccine distribution that may lead to a substantial proportion of perishable vaccines going to waste, say Tinglong Dai a professor of operations management at Johns Hopkins Carey Business School and Christopher S Tang, a distinguished professor at the University of California.
Fulfilment centres can solve the variable demand problem, the writers say. Instead of shipping the shots straight to hospitals or pharmacies, regional fulfilment centres in different districts with pooled inventory could be set up, a method practised by Amazon.